Coronado Industries Signs Exclusive Distribution Agreement for France; Agreement a Key Part of Expansion of Distribution Across Europe.

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTCBB: CNDO) (www.coronadoindustries.com), the manufacturers of unique proprietary pneumatic devices for the noninvasive treatment of glaucoma through its wholly owned subsidiary, Ophthalmic International (www.ophthalmicinternational.com), announced today it has entered into an agreement with Laboratories DOLIAGE (Suresnes, France) covering the sales, marketing and distribution of the company's PNT technology in France. France, one of Europe's largest markets, has an estimated 650,000 glaucoma sufferers, many of whom could benefit from treatment with the company's innovative device.

In making the announcement today, Richard Smith, chairman of Coronado Industries, said the agreement and inclusion of the French market marked a high point in the company's successful expansion across Europe, and said that he was excited to be working with Laboratories DOLIAGE. "DOLIAGE, a company highly focused on servicing the French ophthalmology market, is an ideal company for us to partner with as PNT is rolled out to the French marketplace." Smith went on to say that this agreement differs from distribution agreements Coronado has signed in the past. This time Coronado will be paid for the equipment and rings sold to DOLIAGE but will share in the profits from all sales DOLIAGE makes to the end user. France, being a major market in Europe, will hopefully make this our most lucrative contract to date.

Smith said that past experience has shown that a knowledgeable, well-trained sales force, with access to the Key Opinion Leaders (KOLs), who are often the first to adopt newer technologies, are the keys to the successful introduction of PNT. "DOLIAGE fully understands Coronado's needs and those of the market and is committed to putting the necessary resources behind the product and to ensure that the French medical community understands and embraces PNT." Smith said that as part of our agreement, a clinical trial will be initiated at selected French ophthalmology centers, targeting selected Key Opinion Leaders and large glaucoma centers, to accelerate exposure and acceptance of PNT by the French glaucoma community."

Dr. Francesco Aspes, head of European activity for Coronado Industries, who was a key player in putting this agreement in place, said he looked forward to a long and fruitful relationship with DOLIAGE. "During their evaluation of PNT, they had the opportunity to see firsthand the very positive results Italian ophthalmologists are achieving as they incorporate PNT into their patients' treatment regimes. Seeing the results firsthand was key to their understanding the potential of PNT.

Dr. Aspes said the French KOLs would now be seeing firsthand the power of PNT. Clinical trials such as the one which will be performed in France, and are already under way in Italy and Poland, "are key to getting KOLs on board." Our experience has shown us that as Key Opinion Leaders in each of these countries embrace PNT, then the general glaucoma specialists and ophthalmologists are more willing to utilize the technique."

Dr. Luc Buhannic, president of Laboratories DOLIAGE, said he was very pleased to have DOLIAGE involved in the expansion of such an innovative process for glaucoma treatment, which is perfectly in line with the company strategy. Several French ophthalmologists had the opportunity with DOLIAGE to be included in some patient PNT procedures. They appreciated the simplicity of the actual process, and its excellent acceptance by patients. Dr. Buhannic said he sees a great potential in France for this technology, and is looking forward to a long and profitable relationship with Ophthalmic International.

Dr. John Sharkey, president of Ophthalmic International, re-emphasized the French agreement and said that gaining a foothold in this major market had contributed enormously to the company's international marketing strategy. "We continue to advance our discussions around exclusive deals covering additional European countries. Earlier this year we signed an exclusive agreement with Beijing World Vision covering the registration and distribution of PNT in China. We announced only last week the successful completion of our ISO 13485 audit that opens the way for us to file for a Canadian registration in the coming weeks. All of the progress we have made is a direct result of months of dedicated work by our management team and associates. Our work continues in many other countries and we look forward to issuing more good news as the year progresses," Dr. Sharkey said.

Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.